MAPT and Alzheimer disease: The validity of plasma P-tau as AD biomarker has been verified in neuropathologically confirmed cases (Lantero Rodriguez et al., 2020; Palmqvist et al., 2020), which was not affected by common co-pathologies (such as TDP-43 or α-synuclein pathology) (Smirnov et al., 2022).